findmyKOL

Paul Greenberger, MD

Basic profile

Northwestern University

ORCIDNPI
RegionChicago, IL · MidwestSpecialtyAllergy & ImmunologyFocusRheumatology/Immunology
Last active 2022findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2022Online presenceNot yet checkedPaymentsNone reportedNIH funding1985–1992Why? →

Paul Greenberger is a Rheumatology/Immunology physician affiliated with Northwestern University. OpenAlex indexes 352 publications with 15,471 citations (h-index 55); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Allergy & Immunology profiles in the findmyKOL directory.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
352publications

Distinct works indexed by OpenAlex, matched via ORCID.

15,471citations

Total citations across indexed works.

55h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials
2NIH grants · 1985–1992

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

680 N Lake Shore Dr
Suite 1000
Chicago, IL 606114546

Telephone

312-695-9797

Registry record last updated 8 Jul 2007.

View the NPPES registry record

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Medicare prescribing footprint (2022)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Respiratory

    76%
    Corticosteroid37.5%
    Breo Ellipta26%Symbicort19%Arnuity Ellipta17%Flovent Hfa15%Fluticasone Propionate14%Pulmicort Flexhaler10%
    Part D<11 patients
    Leukotriene Receptor Antagonist22.5%
    Montelukast Sodium84%Zafirlukast16%
    Part D<11 patients

    + 4 more classes in this area

  • Dermatology

    10.2%
    Interleukin-4 Receptor alpha Antagonist10.2%
    Dupixent Syringe100%
    Part D<11 patients
  • Metabolism & gastrointestinal

    9.9%
    Corticosteroid6.3%
    Prednisone100%
    Part D13 patients
    Proton pump inhibitor3.6%
    Omeprazole100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

2 NIH research awards on record, funded 19851992 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”